Medications to treat cocaine use disorders
| Autor: | Andrew J. Saxon, Jonathan Buchholz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug
medicine.medical_specialty business.industry media_common.quotation_subject Addiction MEDLINE Mental health Antidepressive Agents Naltrexone 030227 psychiatry Cocaine-Related Disorders 03 medical and health sciences Psychiatry and Mental health 0302 clinical medicine Disulfiram medicine Cocaine use Humans Anticonvulsants Central Nervous System Stimulants Psychiatry business 030217 neurology & neurosurgery Antipsychotic Agents media_common |
| Zdroj: | Current Opinion in Psychiatry. 32:275-281 |
| ISSN: | 0951-7367 |
| DOI: | 10.1097/yco.0000000000000518 |
| Popis: | Cocaine is a highly addictive substance with serious medical and mental health consequences. Despite these concerns, there are no Food and Drug Administration-approved medications for the treatment of cocaine use disorder (CUD). Although many medication-assisted treatments (MATs) have been investigated, no clear guidelines exist for clinicians treating patients with CUDs.There are a limited number of recent data examining MATs for CUD. Multiple high-quality reviews of existing literature have been performed with psychostimulants, modafinil, bupropion, topiramate and disulfiram showing the most promise. Evidence is limited by heterogeneity of studies, small sample sizes and inconsistent results.The current literature does not strongly support any individual MAT for CUD. Psychosocial interventions, namely contingency management, have the most evidence for treatment of CUD, but it is worth seriously considering MAT for patients who do not respond well to psychosocial interventions alone given limitations in access to care, relatively low risks associated with MAT and significant morbidity associated with CUD. Further research into MAT for CUD is necessary, as the combination of MAT and psychosocial interventions may be better than either alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|